Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
RGNX REGENXBIO Inc. daily Stock Chart
RGNX [NASD]
REGENXBIO Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.78 Insider Own0.60% Shs Outstand37.10M Perf Week-2.36%
Market Cap1.41B Forward P/E- EPS next Y-2.00 Insider Trans-43.65% Shs Float31.17M Perf Month1.33%
Income-102.50M PEG- EPS next Q-0.94 Inst Own91.10% Short Float13.76% Perf Quarter10.45%
Sales52.00M P/S27.10 EPS this Y-194.70% Inst Trans4.45% Short Ratio10.48 Perf Half Y-13.49%
Book/sh11.32 P/B3.29 EPS next Y29.80% ROA-20.50% Target Price- Perf Year-19.06%
Cash/sh7.37 P/C5.05 EPS next 5Y2.00% ROE-22.40% 52W Range20.03 - 54.97 Perf YTD-9.20%
Dividend- P/FCF- EPS past 5Y-68.50% ROI-32.50% 52W High-32.33% Beta1.07
Dividend %- Quick Ratio10.60 Sales past 5Y41.90% Gross Margin77.60% 52W Low85.72% ATR1.91
Employees257 Current Ratio10.60 Sales Q/Q1895.90% Oper. Margin- RSI (14)48.03 Volatility5.45% 5.32%
OptionableYes Debt/Eq0.00 EPS Q/Q-21.80% Profit Margin- Rel Volume0.43 Prev Close38.36
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume409.26K Price37.20
Recom2.10 SMA200.12% SMA50-3.35% SMA200-5.35% Volume175,804 Change-3.02%
Jun-25-20Resumed BofA/Merrill Buy $9
Jun-25-20Resumed BofA/Merrill Buy $60
May-13-20Initiated RBC Capital Mkts Sector Perform $42
Aug-20-19Upgrade SVB Leerink Underperform → Mkt Perform $38 → $37
Jun-18-19Reiterated Chardan Capital Markets Buy $145 → $150
Jun-14-19Resumed Raymond James Outperform
Jun-05-19Reiterated Chardan Capital Markets Buy $127.50 → $145
Feb-25-19Upgrade Evercore ISI In-line → Outperform
Feb-05-19Upgrade Raymond James Outperform → Strong Buy $94
Dec-17-18Reiterated Chardan Capital Markets Buy $127.50
Nov-08-18Reiterated BofA/Merrill Neutral $76 → $84
Aug-08-18Reiterated Chardan Capital Markets Buy $130 → $127.50
Jul-23-18Downgrade BofA/Merrill Buy → Neutral
Jul-10-18Reiterated Chardan Capital Markets Buy $90 → $130
May-09-18Reiterated Barclays Overweight $38 → $48
Apr-09-18Reiterated Chardan Capital Markets Buy $85 → $90
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-13-18Initiated Mizuho Neutral $28
Nov-09-17Resumed Morgan Stanley Overweight $34
Nov-09-17Reiterated Chardan Capital Markets Buy $75 → $85
Jul-08-20 07:05AM  
REGENXBIO Provides Update on Progress of Clinical Programs for Rare Genetic Neurodegenerative Diseases
PR Newswire
Jun-23-20 07:42PM  
Should You Buy Regenxbio Inc (RGNX)?
Insider Monkey
Jun-10-20 07:30AM  
REGENXBIO to Present at the Raymond James Human Health Innovation Conference
PR Newswire
Jun-04-20 08:49AM  
Edited Transcript of RGNX earnings conference call or presentation 7-May-20 8:30pm GMT
Thomson Reuters StreetEvents
May-12-20 09:06AM  
REGENXBIO Inc. (NASDAQ:RGNX) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Simply Wall St.
May-10-20 03:19PM  
Were Hedge Funds Right About Regenxbio Inc (RGNX)?
Insider Monkey
May-07-20 08:31PM  
Regenxbio Inc. (RGNX) Q1 2020 Earnings Call Transcript
Motley Fool
Apr-30-20 04:31PM  
REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
PR Newswire
Apr-28-20 05:38PM  
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 23rd Annual Meeting
PR Newswire -5.57%
12:33PM  
Regenxbio (RGNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks
Apr-27-20 01:55PM  
Should REGENXBIO (NASDAQ:RGNX) Be Disappointed With Their 86% Profit?
Simply Wall St.
Apr-23-20 09:12AM  
Another 140,000 apply for unemployment benefits in D.C., Md. and Va.
American City Business Journals
Apr-22-20 06:30AM  
REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
PR Newswire +5.02%
Mar-31-20 04:05PM  
REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder
GlobeNewswire
Mar-13-20 10:02AM  
Should You Worry About REGENXBIO Inc.'s (NASDAQ:RGNX) CEO Pay Cheque?
Simply Wall St. +5.87%
09:34AM  
These local companies took the biggest one-day hits on Wall Street on Thursday
American City Business Journals
Mar-09-20 07:00AM  
REGENXBIO to Present at the Barclays Global Healthcare Conference
PR Newswire -10.24%
02:26AM  
Edited Transcript of RGNX earnings conference call or presentation 26-Feb-20 9:30pm GMT
Thomson Reuters StreetEvents
Mar-02-20 08:45AM  
These local companies have taken the biggest hits on Wall Street during current sell-off
American City Business Journals
Feb-26-20 07:15PM  
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
Zacks
04:05PM  
REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
PR Newswire
02:34PM  
Novavax is working to advance a potential coronavirus vaccine. So are competitors.
American City Business Journals
Feb-25-20 08:10AM  
Coronavirus fears lead to Wall Street sell-off. Here are the D.C.-area companies hit the hardest.
American City Business Journals -5.39%
Feb-19-20 12:31PM  
Earnings Preview: Regenxbio (RGNX) Q4 Earnings Expected to Decline
Zacks
Jan-29-20 07:00AM  
REGENXBIO Announces Presentations at the 16th Annual WORLDSymposium 2020
PR Newswire
Jan-28-20 01:12PM  
How REGENXBIO Inc. (NASDAQ:RGNX) Can Impact Your Portfolio Volatility
Simply Wall St.
Jan-10-20 10:08AM  
Applied Genetic Stock Up on Favorable Eye Therapy Study Data
Zacks
Jan-09-20 08:30PM  
Edited Transcript of RGNX earnings conference call or presentation 5-Nov-19 9:30pm GMT
Thomson Reuters StreetEvents
07:00AM  
REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update
PR Newswire
Dec-19-19 04:22PM  
These Hedge Funds Cashed Out Of Regenxbio Inc (RGNX) Too Early
Insider Monkey
Dec-18-19 07:41AM  
REGENXBIO Announces Interim Data from Phase I/II Trial of RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)
PR Newswire
Dec-16-19 09:30AM  
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR Newswire
Dec-11-19 03:27PM  
Top stock picks for 2020: Standout small companies
MarketWatch
02:07PM  
We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth
Simply Wall St.
Dec-04-19 05:00AM  
Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018
American City Business Journals
Nov-06-19 04:15PM  
The FDA Paused This Biotech's Gene Therapy Study And Shares Tumbled
Investor's Business Daily
Nov-05-19 06:25PM  
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
Zacks
04:05PM  
REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights
PR Newswire
Nov-02-19 12:00PM  
What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One
Investor's Business Daily
Oct-31-19 04:30AM  
8 Undervalued Biotech Stocks to Watch Now
Investopedia
Oct-30-19 07:05AM  
Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector in AAV Gene Therapy Delivery
GlobeNewswire -11.96%
Oct-29-19 07:00AM  
REGENXBIO To Host Conference Call on November 5 to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights
PR Newswire
Oct-25-19 12:49PM  
Announcing: REGENXBIO (NASDAQ:RGNX) Stock Increased An Energizing 142% In The Last Three Years
Simply Wall St. +5.48%
09:36AM  
Is Regenxbio Inc (RGNX) Going to Burn These Hedge Funds?
Insider Monkey
Oct-17-19 07:00AM  
REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress
PR Newswire
Oct-15-19 02:48PM  
RegenxBio gets positive interim data for eye disease treatment
American City Business Journals +8.36%
10:57AM  
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA
Zacks
Oct-11-19 07:15PM  
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
PR Newswire
Oct-10-19 10:11AM  
Wet AMD Space in Focus: New Drug Approvals & Key Advancements
Zacks
Oct-06-19 05:15PM  
The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck
Benzinga
Oct-02-19 08:31AM  
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita
Zacks
Oct-01-19 01:43PM  
Biotech Roundtable: How to Invest in Medicines Future
Barrons.com
Sep-30-19 07:00AM  
REGENXBIO to Present at The Chardan 3rd Annual Genetic Medicines Conference
PR Newswire +6.75%
Sep-19-19 08:29AM  
An Intrinsic Calculation For REGENXBIO Inc. (NASDAQ:RGNX) Suggests It's 21% Undervalued
Simply Wall St.
Sep-13-19 08:44AM  
REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%
Zacks
Sep-09-19 12:58PM  
This Rockville biotech has added another deal to its growth plan
American City Business Journals
Sep-04-19 09:42AM  
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
Zacks
07:00AM  
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314
PR Newswire
Aug-28-19 04:05PM  
REGENXBIO to Present at Upcoming Investor Conferences
PR Newswire
01:31PM  
3 Top Biotech Stocks to Buy Right Now
Motley Fool
Aug-27-19 07:00AM  
REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October
PR Newswire
Aug-23-19 07:36AM  
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
Zacks
Aug-21-19 07:15PM  
Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $563,250 of Shares
GuruFocus.com
Aug-12-19 04:33AM  
Edited Transcript of RGNX earnings conference call or presentation 7-Aug-19 8:30pm GMT
Thomson Reuters StreetEvents
Aug-09-19 10:14AM  
Regenxbio Inc. (RGNX) Q2 2019 Earnings Call Transcript
Motley Fool
Aug-07-19 06:15PM  
Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates
Zacks
04:05PM  
REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
PR Newswire
Aug-06-19 02:20PM  
Is REGENXBIO Inc.'s (NASDAQ:RGNX) CEO Overpaid Relative To Its Peers?
Simply Wall St.
Jul-31-19 07:07AM  
REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector
PR Newswire
Jul-30-19 04:05PM  
REGENXBIO To Host Conference Call on August 7 to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights
PR Newswire
Jul-24-19 04:10PM  
REGENXBIO Expands Pipeline Using NAV Vectors to Deliver Therapeutic Antibodies for the Treatment of Hereditary Angioedema and Neurodegenerative Diseases
PR Newswire
04:05PM  
REGENXBIO and Neurimmune Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases
PR Newswire
Jul-23-19 06:15PM  
Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $742,350 of Shares
GuruFocus.com
Jul-02-19 08:41AM  
Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?
Zacks -8.14%
Jun-19-19 09:07PM  
Heres What Hedge Funds Think About Regenxbio Inc (RGNX)
Insider Monkey
Jun-11-19 07:00AM  
REGENXBIO to Present at the Raymond James 2019 Life Sciences and MedTech Conference
PR Newswire
Jun-03-19 02:32PM  
Edited Transcript of RGNX earnings conference call or presentation 7-May-19 8:30pm GMT
Thomson Reuters StreetEvents
May-28-19 01:47PM  
FDA approves most expensive gene therapy ever and here is its connection to Penn
American City Business Journals +7.19%
11:25AM  
REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%
Zacks
May-24-19 07:46PM  
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio
Motley Fool +7.44%
01:14PM  
REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform
PR Newswire
May-15-19 07:00AM  
REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies
PR Newswire
May-08-19 07:00AM  
REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
PR Newswire -8.52%
May-07-19 09:24PM  
Regenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript
Motley Fool
06:36PM  
Regenxbio: 1Q Earnings Snapshot
Associated Press
04:05PM  
REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
PR Newswire
May-02-19 12:40PM  
Is Regenxbio Inc (RGNX) A Good Stock To Buy?
Insider Monkey
Apr-30-19 07:00AM  
REGENXBIO to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
PR Newswire
Apr-22-19 04:15PM  
A Second Baby Died In A Gene Therapy Study Slugging This Biotech Stock
Investor's Business Daily -7.80%
Apr-19-19 02:48PM  
Top Gene-Sequencing Stocks for 2019
Motley Fool
01:22PM  
Did The Underlying Business Drive REGENXBIO's (NASDAQ:RGNX) Lovely 384% Share Price Gain?
Simply Wall St.
Apr-17-19 07:00AM  
REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer
PR Newswire
Apr-15-19 04:05PM  
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting
PR Newswire
Apr-08-19 09:45AM  
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
Zacks
Apr-03-19 08:16AM  
3 Small-Cap Biotech Stocks to Watch Now
Motley Fool
Mar-26-19 07:15AM  
New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex Consolidated Revenues, Company Growth, and Expectations for 2019
GlobeNewswire
Mar-10-19 10:36AM  
10 Stocks For The Gene Therapy Revolution
Investopedia
Mar-08-19 10:40AM  
Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?
Motley Fool
Mar-06-19 07:00AM  
REGENXBIO to Participate in Upcoming Investor Conferences
PR Newswire -5.56%
Mar-05-19 08:44AM  
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher
Zacks
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vasista VittalChief Financial OfficerMay 11Option Exercise13.095006,545207,215May 12 04:16 PM
Vasista VittalChief Financial OfficerMay 11Sale40.0050020,000206,715May 12 04:16 PM
Vasista VittalChief Financial OfficerMay 08Option Exercise13.092,50032,725213,715May 12 04:16 PM
Vasista VittalChief Financial OfficerMay 08Sale40.187,000281,260206,715May 12 04:16 PM
Vasista VittalChief Financial OfficerApr 24Option Exercise13.093,00039,270223,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerApr 24Sale40.1112,000481,320211,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerApr 23Option Exercise13.093,00039,270223,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerApr 23Sale40.003,000120,000220,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerMar 31Option Exercise0.8510,0008,500220,215Apr 02 04:22 PM
Simpson CurranSVP, Product Development & CTOFeb 11Option Exercise22.006,633145,92616,512Feb 12 04:27 PM
Simpson CurranSVP, Product Development & CTOFeb 11Sale50.4912,564634,4113,948Feb 12 04:27 PM
HAYDEN DONALD J JRDirectorFeb 10Option Exercise0.8524,80021,08024,800Feb 12 04:22 PM
Vasista VittalChief Financial OfficerFeb 10Option Exercise13.093,00039,270225,021Feb 12 04:24 PM
Simpson CurranSVP, Product Development & CTOFeb 10Option Exercise27.1031,660858,09854,308Feb 12 04:27 PM
Simpson CurranSVP, Product Development & CTOFeb 10Sale50.2244,4292,231,2249,879Feb 12 04:27 PM
Vasista VittalChief Financial OfficerFeb 10Sale50.0714,806741,352210,215Feb 12 04:24 PM
HAYDEN DONALD J JRDirectorFeb 10Sale50.1124,8001,242,7280Feb 12 04:22 PM
Simpson CurranSVP, Product Development & CTOFeb 05Option Exercise18.085,13792,88628,285Feb 07 04:23 PM
HAYDEN DONALD J JRDirectorFeb 05Option Exercise0.852,0001,7002,000Feb 07 04:19 PM
Simpson CurranSVP, Product Development & CTOFeb 05Sale50.005,637281,85022,648Feb 07 04:23 PM
Vasista VittalChief Financial OfficerFeb 05Sale50.0030015,000222,021Feb 07 04:21 PM
HAYDEN DONALD J JRDirectorFeb 05Sale50.002,000100,0000Feb 07 04:19 PM
HAYDEN DONALD J JRDirectorJan 17Option Exercise0.853,2002,7203,200Jan 21 04:16 PM
Simpson CurranSVP, Product Development & CTOJan 17Option Exercise23.365,122119,66929,070Jan 21 04:18 PM
Vasista VittalChief Financial OfficerJan 17Sale50.002,394119,700222,321Jan 21 04:17 PM
Simpson CurranSVP, Product Development & CTOJan 17Sale50.005,922296,10023,148Jan 21 04:18 PM
HAYDEN DONALD J JRDirectorJan 17Sale50.013,200160,0320Jan 21 04:16 PM
HAYDEN DONALD J JRDirectorJan 14Option Exercise0.8530,00025,50030,000Jan 16 04:18 PM
HAYDEN DONALD J JRDirectorJan 14Sale45.6030,0001,368,0000Jan 16 04:18 PM
Vasista VittalChief Financial OfficerJan 08Option Exercise13.093,00039,270232,215Jan 10 04:20 PM
Vasista VittalChief Financial OfficerJan 08Sale41.757,500313,152224,715Jan 10 04:20 PM
Simpson CurranSVP, Product Development & CTODec 09Sale43.7415,552680,24823,948Dec 11 04:24 PM
Mills Kenneth T.President and CEOSep 19Option Exercise0.855,0004,250251,000Sep 23 04:12 PM
Mills Kenneth T.President and CEOSep 19Sale39.7510,000397,497241,000Sep 23 04:12 PM
Christmas Patrick J.SVP, General CounselSep 12Option Exercise12.105,00060,5008,058Sep 16 04:24 PM
Christmas Patrick J.SVP, General CounselSep 12Sale42.005,486230,4122,572Sep 16 04:24 PM
Mills Kenneth T.President and CEOAug 19Option Exercise0.8515,00012,750261,000Aug 21 04:17 PM
Mills Kenneth T.President and CEOAug 19Sale37.5515,000563,243246,000Aug 21 04:17 PM
Mills Kenneth T.President and CEOJul 19Option Exercise0.8515,00012,750261,000Jul 23 04:33 PM
Christmas Patrick J.SVP, General CounselJul 19Option Exercise19.504,90095,5507,958Jul 22 04:29 PM
Christmas Patrick J.SVP, General CounselJul 19Sale50.034,900245,1473,058Jul 22 04:29 PM
Mills Kenneth T.President and CEOJul 19Sale49.4915,000742,311246,000Jul 23 04:33 PM
Christmas Patrick J.SVP, General CounselJul 18Option Exercise19.501001,9503,158Jul 22 04:29 PM
Christmas Patrick J.SVP, General CounselJul 18Sale50.001005,0003,058Jul 22 04:29 PM
open in yahoo | open in reuters | open in google